First-in-human phase 1 clinical trial of pharmacological ascorbate combined with radiation and temozolomide for newly diagnosed glioblastoma

PURPOSE: Standard treatment for glioblastoma (GBM) includes surgery, radiation (RT), and temozolomide (TMZ), yielding a median overall survival (OS) of ≈14 months. Preclinical models suggest pharmacological ascorbate (P-AscH(−)) enhances RT/TMZ anti-tumor effect in GBM. We evaluated the safety of ad...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Cancer Res
Main Authors: Allen, Bryan G., Bodeker, Kellie L., Smith, Mark C., Monga, Varun, Sandhu, Sonia, Hohl, Raymond, Carlisle, Thomas, Brown, Heather, Hollenbeck, Nancy, Vollstedt, Sandy, Greenlee, Jeremy D., Howard, Matthew A., Mapuskar, Kranti A., Seyedin, Steven N., Caster, Joseph M., Jones, Karra A., Cullen, Joseph J., Berg, Daniel, Wagner, Brett A., Buettner, Garry R., TenNapel, Mindi J., Smith, Brian J., Spitz, Douglas R., Buatti, John M.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6858950/
https://ncbi.nlm.nih.gov/pubmed/31427282
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-0594
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados